The number of patients with chronic kidney disease is estimated to be 13 million, and the number of dialysis patients exceeds 340,000. The annual medical cost of dialysis alone is close to 1.7 trillion yen, and the quality of life of patients is not good. The number of patients is increasing year by year, and if the situation is left unchecked, it is expected to become catastrophic. Prevention against developing severe stage is an important strategy, but drug therapy for renal disease is limited. Although potential breakthrough drugs such as SGLT2 inhibitors and bardoxolone methyl are currently being tested for pharmacological effects and efficacy, efforts to increase the number of options are needed. In this talk, I would like to introduce the current status and future of these renal drug therapies.